caa a22 4500 445808535 CHVBK 20180317145204.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s00415-011-6087-9 doi (NATIONALLICENCE)springer-10.1007/s00415-011-6087-9 Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer's disease [Elektronische Daten] [Jihye Choi, Ho-Won Lee, Kyoungho Suk] Previously, chitinase 3-like 1 (CHI3L1) protein level was increased in various inflammatory conditions and cancers. This study was aimed to evaluate the plasma CHI3L1 level as a potential prognostic biomarker for Alzheimer's disease (AD). Forty-nine patients with mild cognitive impairment (MCI), 61 patients with mild to severe AD, and 35 healthy elderly controls were recruited for this study. They were given a comprehensive neuropsychological test battery including a mini-mental status examination (MMSE), clinical dementia rating (CDR), and neuropsychiatric inventory (NPI). The CHI3L1 levels were measured using a specific enzyme-linked immunosorbent assay in the plasma and cerebrospinal fluid (CSF). A significant increase in the mean plasma level of CHI3L1 was found in early AD patients compared to control subjects and MCI patients. No significant difference was found between MCI patients and controls. There was a significant positive correlation between CHI3L1 levels and neuropsychological test scores such as CDR and NPI in MCI and early AD patients. Our results demonstrate that CHI3L1 plasma levels are elevated in early AD compared to control or MCI patients. Thus, CHI3L1 plasma levels may be useful as a biomarker, reflecting disease severity in AD patients. Springer-Verlag, 2011 Alzheimer's diseases (AD) nationallicence Mild cognitive impairment (MCI) nationallicence Amnestic mild cognitive impairment (aMCI) nationallicence Chitinase 3-like 1 (CHI3L1) nationallicence Biomarker nationallicence Choi Jihye Department of Pharmacology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, 101 Dong-In, Joong-gu, Daegu, Korea aut Lee Ho-Won Department of Neurology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, 101 Dong-In, Joong-gu, 700-422, Daegu, Korea aut Suk Kyoungho Department of Pharmacology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, 101 Dong-In, Joong-gu, Daegu, Korea aut Journal of Neurology Springer-Verlag 258/12(2011-12-01), 2181-2185 0340-5354 258:12<2181 2011 258 415 https://doi.org/10.1007/s00415-011-6087-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-011-6087-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Choi Jihye Department of Pharmacology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, 101 Dong-In, Joong-gu, Daegu, Korea aut NATIONALLICENCE 700 1- Lee Ho-Won Department of Neurology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, 101 Dong-In, Joong-gu, 700-422, Daegu, Korea aut NATIONALLICENCE 700 1- Suk Kyoungho Department of Pharmacology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, 101 Dong-In, Joong-gu, Daegu, Korea aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/12(2011-12-01), 2181-2185 0340-5354 258:12<2181 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer